Gioacchino Catania

Dr. Gioacchino Catania

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
GCGioacchino Catania
Gioacchino Catania
FMFederico Monaco
Federico Monaco
GLGiulia Limberti
Giulia Limberti
MAManuela Alessio
Manuela Alessio
IMIolanda De Martino
Iolanda De Martino
Vittorio FuscoVittorio Fusco
Vittorio Fusco
Bisphosphonates (BPs) are administered to Multiple Myeloma (MM) patients with bone lytic lesion. Osteonecrosis of the Jaw (ONJ) is a complication reported since 2003 in patients treated with intravenous (IV) BPs such as zoledronic acid and pamidronate, with 6%–26.3% frequency in early literature series, before some preventive measures were recommended. We evaluated the occurrence of ONJ with and without dental preventive measures in MM patients treated with BPs in our centre between 1996 and 2015. Since 2005, MM patients (already under treatment or before treatment) underwent a baseline mouth assessment (dental visit, Rx orthopantomography, and eventual tooth avulsion or dental care if necessary) and were followed by a multidisciplinary team. We reviewed the charts of 119 MM patients receiving IV BPs, classified into 3 groups: (a) “historic group” (21 patients who had started BP treatment in years before the awareness of ONJ); (b) “screening group” (20 patients starting BPs without baseline evaluation); and (c) “prevention group” (78 patients starting therapy only after baseline preventive assessment and eventual dental care measures). ONJ was observed in 3/21 patients (14.2%) from group a, in 2/20 patients (10%) from group b, and in no patients from group c (0%). Notably, the median number of IV BP administrations decreased after 2005. Our data confirmed a meaningful reduction of ONJ risk in MM patients treated with BPs if preventive measures are applied. Both implementation of prevention measures and reduction of cumulative doses of IV BPs could have contributed to a decreased incidence of ONJ.

27 February 2026 in Blood Advances
Verified
Journal Article
Open access
EMEnrica antonia Martino
Enrica antonia Martino
APAnnalisa Pitino
Annalisa Pitino
EVErnesto Vigna
Ernesto Vigna
RPRaffaella Pasquale
Raffaella Pasquale
IFIsacco Ferrarini
Isacco Ferrarini
MGMassimo Gentile
Massimo Gentile
Bruton tyrosine kinase inhibitors (BTKis) have dramatically changed the therapeutic landscape of chronic lymphocytic leukemia (CLL), with ibrutinib, first-in-class, demonstrating durable efficacy even in high-risk patients. However, off-target adverse events (AEs) have raised concerns, prompting the development of more selective second-generation BTKis, such as zanubrutinib, designed to improve tolerability while maintaining efficacy. Despite encouraging results from clinical trials, real-world data comparing zanubrutinib with ibrutinib remain limited. In this multicenter, retrospective study, we analyzed 934 patients with CLL treated outside clinical trials, including 393 receiving zanubrutinib and 541 receiving ibrutinib. We evaluated time to treatment discontinuation (TTD) and time to next treatment or death (TTNTD) in both the overall cohort and a propensity score–matched population. Patients who were treated with zanubrutinib experienced lower 12-month discontinuation rates (overall: 12.6% vs 21.4%; matched: 12.4% vs 20.2%) and higher 12-month TTNTD rates (overall: 91.9% vs 83.0%; matched: 93.2% vs 83.4%). Multivariable analyses confirmed zanubrutinib as an independent predictor of longer TTD and TTNTD, whereas high-risk features, including age, relapsed/refractory disease, Binet stage C, TP53 disruption, Eastern Cooperative Oncology Group 2 to 3, and congestive heart failure, were consistently associated with poorer outcomes. AEs leading to discontinuation, particularly atrial fibrillation, bleeding, and infections, were less frequent with zanubrutinib, reflecting its favorable safety profile. These findings provide real-world evidence that zanubrutinib offers more durable disease control and improved persistence compared with ibrutinib, reinforcing its clinical value as a preferred second-generation BTKi. Nevertheless, the relatively short follow-up for zanubrutinib warrants cautious interpretation of long-term outcomes, and underscores the need for ongoing observation to fully characterize its durability and safety.

5 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
Alberto FresaAlberto Fresa
Alberto Fresa
FAFrancesco Autore
Francesco Autore
APAlfonso Piciocchi
Alfonso Piciocchi
GCGioacchino Catania
Gioacchino Catania
Andrea VisentinAndrea Visentin
Andrea Visentin
LLLuca Laurenti
Luca Laurenti

1 January 2014 in Leukemia Research Reports
Verified
Journal Article
Open access
GCGioacchino Catania
Gioacchino Catania
FZFrancesco Zallio
Francesco Zallio
FMFederico Monaco
Federico Monaco
MCMaria Teresa Corsetti
Maria Teresa Corsetti
NTNicol Trincheri
Nicol Trincheri
MPMassimo Pini
Massimo Pini
Hepatosplenic T cell lymphoma (HSTCL) is a type of hematologic neoplasia with a poor prognosis and a high frequency of refractoriness to conventional chemotherapy. The results obtained by high dose chemotherapy followed by autologous stem cells transplantation seem to be a more effective option but still unsatisfactory. Also the role of allogeneic stem cell transplantation is still unclear, although the few cases reported on the literature would seem to show good results in overall survival rates. In this paper, we reported the patient׳s medical history affected by a αβ variant of hepatosplenic T cell successfully rescued with a haploidentical transplant.

29 May 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
LLLuca Laurenti
Luca Laurenti
FGFeliciana Guglielmi
Feliciana Guglielmi
AMAntonio Mosca
Antonio Mosca
CVCandida Vitale
Candida Vitale
MMMaria Chiara Montalbano
Maria Chiara Montalbano
IIIdanna Innocenti
Idanna Innocenti
Luca Laurenti, Feliciana Guglielmi, Antonio Mosca, Candida Vitale, Maria Chiara Montalbano, Gianmarco Favrin, Isacco Ferrarini, Andrea Galitzia, Raffaella